13 results on '"Shaw, Lauren"'
Search Results
2. Booster COVID-19 Vaccinations Among Persons Aged ≥5 Years and Second Booster COVID-19 Vaccinations Among Persons Aged ≥50 Years -- United States, August 13, 2021-August 5, 2022.
- Author
-
Fast, Hannah E., Murthy, Bhavini Patel, Zell, Elizabeth, Lu Meng, Murthy, Neil, Saelee, Ryan, Peng-jun Lu, Yoonjae Kang, Shaw, Lauren, Gibbs-Scharf, Lynn, and Harris, LaTreace
- Subjects
COVID-19 vaccines ,BOOSTER vaccines ,OLDER people ,COVID-19 - Published
- 2022
- Full Text
- View/download PDF
3. COVID-19 Vaccine Provider Availability and Vaccination Coverage Among Children Aged 5-11 Years -- United States, November 1, 2021-April 25, 2022.
- Author
-
DeCuir, Jennifer, Lu Meng, Yi Pan, Vogt, Tara, Chatham-Stevens, Kevin, Meador, Seth, Shaw, Lauren, Black, Carla L., and Harris, LaTreace Q.
- Subjects
COVID-19 vaccines ,VACCINATION coverage ,VACCINATION of children ,CHILDREN'S health - Published
- 2022
4. Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties - United States, December 14, 2020-January 31, 2022.
- Author
-
Saelee, Ryan, Zell, Elizabeth, Murthy, Bhavini Patel, Castro-Roman, Patricia, Fast, Hannah, Lu Meng, Shaw, Lauren, Gibbs-Scharf, Lynn, Chorba, Terence, Harris, LaTreace Q., Murthy, Neil, and Meng, Lu
- Abstract
Higher COVID-19 incidence and mortality rates in rural than in urban areas are well documented (1). These disparities persisted during the B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant surges during late 2021 and early 2022 (1,2). Rural populations tend to be older (aged ≥65 years) and uninsured and are more likely to have underlying medical conditions and live farther from facilities that provide tertiary medical care, placing them at higher risk for adverse COVID-19 outcomes (2). To better understand COVID-19 vaccination disparities between urban and rural populations, CDC analyzed county-level vaccine administration data among persons aged ≥5 years who received their first dose of either the BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccine or a single dose of the Ad.26.COV2.S (Janssen [Johnson & Johnson]) COVID-19 vaccine during December 14, 2020-January 31, 2022, in 50 states and the District of Columbia (DC). COVID-19 vaccination coverage with ≥1 doses in rural areas (58.5%) was lower than that in urban counties (75.4%) overall, with similar patterns across age groups and sex. Coverage with ≥1 doses varied among states: 46 states had higher coverage in urban than in rural counties, one had higher coverage in rural than in urban counties. Three states and DC had no rural counties; thus, urban-rural differences could not be assessed. COVID-19 vaccine primary series completion was higher in urban than in rural counties. However, receipt of booster or additional doses among primary series recipients was similarly low between urban and rural counties. Compared with estimates from a previous study of vaccine coverage among adults aged ≥18 years during December 14, 2020-April 10, 2021, these urban-rural disparities among those now eligible for vaccination (aged ≥5 years) have increased more than twofold through January 2022, despite increased availability and access to COVID-19 vaccines. Addressing barriers to vaccination in rural areas is critical to achieving vaccine equity, reducing disparities, and decreasing COVID-19-related illness and death in the United States (2). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years - United States, August 13, 2021-November 19, 2021.
- Author
-
Fast, Hannah E., Zell, Elizabeth, Patel Murthy, Bhavini, Murthy, Neil, Lu Meng, Gibbs Scharf, Lynn, Black, Carla L., Shaw, Lauren, Chorba, Terence, Harris, LaTreace Q., Murthy, Bhavini Patel, Meng, Lu, and Scharf, Lynn Gibbs
- Abstract
Vaccination against SARS-CoV-2 (the virus that causes COVID-19) is highly effective at preventing hospitalization due to SARS-CoV-2 infection and booster and additional primary dose COVID-19 vaccinations increase protection (1-3). During August-November 2021, a series of Emergency Use Authorizations and recommendations, including those for an additional primary dose for immunocompromised persons and a booster dose for persons aged ≥18 years, were approved because of reduced immunogenicity in immunocompromised persons, waning vaccine effectiveness over time, and the introduction of the highly transmissible B.1.617.2 (Delta) variant (4,5). Adults aged ≥65 years are at increased risk for COVID-19-associated hospitalization and death and were one of the populations first recommended a booster dose in the U.S. (5,6). Data on COVID-19 vaccinations reported to CDC from 50 states, the District of Columbia (DC), and eight territories and freely associated states were analyzed to ascertain coverage with booster or additional primary doses among adults aged ≥65 years. During August 13-November 19, 2021, 18.7 million persons aged ≥65 years received a booster or additional primary dose of COVID-19 vaccine, constituting 44.1% of 42.5 million eligible* persons in this age group who previously completed a primary vaccination series.† Coverage was similar by sex and age group, but varied by primary series vaccine product and race and ethnicity, ranging from 30.3% among non-Hispanic American Indian or Alaska Native persons to 50.5% among non-Hispanic multiple/other race persons. Strategic efforts are needed to encourage eligible persons aged ≥18 years, especially those aged ≥65 years and those who are immunocompromised, to receive a booster and/or additional primary dose to ensure maximal protection against COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Influenza Vaccinations During the COVID-19 Pandemic - 11 U.S. Jurisdictions, September-December 2020.
- Author
-
Roman, Patricia Castro, Kirtland, Karen, Zell, Elizabeth R., Jones-Jack, Nkenge, Shaw, Lauren, Shrader, Lauren, Sprague, Carrie, Schultz, Jessica, Quan Le, Nalla, Abhinav, Kuramoto, Sydney, Cheng, Iris, Woinarowicz, Mary, Robison, Steve, Robinson, Shannon, Meder, Kelley, Murphy, Ashley, Gibbs-Scharf, Lynn, Harris, LaTreace, and Murthy, Bhavini Patel
- Abstract
Influenza causes considerable morbidity and mortality in the United States. Between 2010 and 2020, an estimated 9-41 million cases resulted in 140,000-710,000 hospitalizations and 12,000-52,000 deaths annually (1). As the United States enters the 2021-22 influenza season, the potential impact of influenza illnesses is of concern given that influenza season will again coincide with the ongoing COVID-19 pandemic, which could further strain overburdened health care systems. The Advisory Committee on Immunization Practices (ACIP) recommends routine annual influenza vaccination for the 2021-22 influenza season for all persons aged ≥6 months who have no contraindications (2). To assess the potential impact of the COVID-19 pandemic on influenza vaccination coverage, the percentage change between administration of at least 1 dose of influenza vaccine during September-December 2020 was compared with the average administered in the corresponding periods in 2018 and 2019. The data analyzed were reported from 11 U.S. jurisdictions with high-performing state immunization information systems.* Overall, influenza vaccine administration was 9.0% higher in 2020 compared with the average in 2018 and 2019, combined. However, in 2020, the number of influenza vaccine doses administered to children aged 6-23 months and children aged 2-4 years, was 13.9% and 11.9% lower, respectively than the average for each age group in 2018 and 2019. Strategic efforts are needed to ensure high influenza vaccination coverage among all age groups, especially children aged 6 months-4 years who are not yet eligible to receive a COVID-19 vaccine. Administration of influenza vaccine and a COVID-19 vaccine among eligible populations is especially important to reduce the potential strain that influenza and COVID-19 cases could place on health care systems already overburdened by COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. COVID-19 Vaccination Coverage Among Adolescents Aged 12-17 Years - United States, December 14, 2020-July 31, 2021.
- Author
-
Murthy, Bhavini Patel, Zell, Elizabeth, Saelee, Ryan, Murthy, Neil, Lu Meng, Meador, Seth, Reed, Kirsten, Shaw, Lauren, Gibbs-Scharf, Lynn, McNaghten, A. D., Patel, Anita, Stokley, Shannon, Flores, Stephen, Yoder, Jonathan S., Black, Carla L., Harris, LaTreace Q., and Meng, Lu
- Subjects
COVID-19 vaccines ,MEDICAL personnel ,TEENAGERS ,SOCIAL emotional learning ,VACCINE hesitancy - Abstract
Although severe COVID-19 illness and hospitalization are more common among adults, these outcomes can occur in adolescents (1). Nearly one third of adolescents aged 12-17 years hospitalized with COVID-19 during March 2020-April 2021 required intensive care, and 5% of those hospitalized required endotracheal intubation and mechanical ventilation (2). On December 11, 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine for adolescents aged 16-17 years; on May 10, 2021, the EUA was expanded to include adolescents aged 12-15 years; and on August 23, 2021, FDA granted approval of the vaccine for persons aged ≥16 years. To assess progress in adolescent COVID-19 vaccination in the United States, CDC assessed coverage with ≥1 dose* and completion of the 2-dose vaccination series† among adolescents aged 12-17 years using vaccine administration data for 49 U.S. states (all except Idaho) and the District of Columbia (DC) during December 14, 2020-July 31, 2021. As of July 31, 2021, COVID-19 vaccination coverage among U.S. adolescents aged 12-17 years was 42.4% for ≥1 dose and 31.9% for series completion. Vaccination coverage with ≥1 dose varied by state (range = 20.2% [Mississippi] to 70.1% [Vermont]) and for series completion (range = 10.7% [Mississippi] to 60.3% [Vermont]). By age group, 36.0%, 40.9%, and 50.6% of adolescents aged 12-13, 14-15, and 16-17 years, respectively, received ≥1 dose; 25.4%, 30.5%, and 40.3%, respectively, completed the vaccine series. Improving vaccination coverage and implementing COVID-19 prevention strategies are crucial to reduce COVID-19-associated morbidity and mortality among adolescents and to facilitate safer reopening of schools for in-person learning. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties - United States, December 14, 2020-April 10, 2021.
- Author
-
Murthy, Bhavini Patel, Sterrett, Natalie, Weller, Daniel, Zell, Elizabeth, Reynolds, Laura, Toblin, Robin L., Murthy, Neil, Kriss, Jennifer, Rose, Charles, Cadwell, Betsy, Wang, Alice, Ritchey, Matthew D., Gibbs-Scharf, Lynn, Qualters, Judith R., Shaw, Lauren, Brookmeyer, Kathryn A., Clayton, Heather, Eke, Paul, Adams, Laura, and Zajac, Julie
- Subjects
COVID-19 vaccines ,HEALTH services administration ,MEDICAL personnel ,HEALTH facilities ,COUNTIES ,RURAL nursing - Abstract
Approximately 60 million persons in the United States live in rural counties, representing almost one fifth (19.3%) of the population.* In September 2020, COVID-19 incidence (cases per 100,000 population) in rural counties surpassed that in urban counties (1). Rural communities often have a higher proportion of residents who lack health insurance, live with comorbidities or disabilities, are aged ≥65 years, and have limited access to health care facilities with intensive care capabilities, which places these residents at increased risk for COVID-19-associated morbidity and mortality (2,3). To better understand COVID-19 vaccination disparities across the urban-rural continuum, CDC analyzed county-level vaccine administration data among adults aged ≥18 years who received their first dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine, or a single dose of the Janssen COVID-19 vaccine (Johnson & Johnson) during December 14, 2020-April 10, 2021 in 50 U.S. jurisdictions (49 states and the District of Columbia [DC]). Adult COVID-19 vaccination coverage was lower in rural counties (38.9%) than in urban counties (45.7%) overall and among adults aged 18-64 years (29.1% rural, 37.7% urban), those aged ≥65 years (67.6% rural, 76.1% urban), women (41.7% rural, 48.4% urban), and men (35.3% rural, 41.9% urban). Vaccination coverage varied among jurisdictions: 36 jurisdictions had higher coverage in urban counties, five had higher coverage in rural counties, and five had similar coverage (i.e., within 1%) in urban and rural counties; in four jurisdictions with no rural counties, the urban-rural comparison could not be assessed. A larger proportion of persons in the most rural counties (14.6%) traveled for vaccination to nonadjacent counties (i.e., farther from their county of residence) compared with persons in the most urban counties (10.3%). As availability of COVID-19 vaccines expands, public health practitioners should continue collaborating with health care providers, pharmacies, employers, faith leaders, and other community partners to identify and address barriers to COVID-19 vaccination in rural areas (2). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons - United States, December 14, 2020-February 14, 2021.
- Author
-
Kriss, Jennifer L., Reynolds, Laura E., Wang, Alice, Stokley, Shannon, Cole, Matthew M., Harris, LaTreace Q., Shaw, Lauren K., Black, Carla L., Singleton, James A., Fitter, David L., Rose, Dale A., Ritchey, Matthew D., Toblin, Robin L., and CDC COVID-19 Vaccine Task Force
- Abstract
In December 2020, two COVID-19 vaccines (Pfizer-BioNTech and Moderna) received Emergency Use Authorization from the Food and Drug Administration.*,† Both vaccines require 2 doses for a completed series. The recommended interval between doses is 21 days for Pfizer-BioNTech and 28 days for Moderna; however, up to 42 days between doses is permissible when a delay is unavoidable.§ Two analyses of COVID-19 vaccine administration data were conducted among persons who initiated the vaccination series during December 14, 2020-February 14, 2021, and whose doses were reported to CDC through February 20, 2021. The first analysis was conducted to determine whether persons who received a first dose and had sufficient time to receive the second dose (i.e., as of February 14, 2021, >25 days from receipt of Pfizer-BioNTech vaccine or >32 days from receipt of Moderna vaccine had elapsed) had received the second dose. A second analysis was conducted among persons who received a second COVID-19 dose by February 14, 2021, to determine whether the dose was received during the recommended dosing interval, which in this study was defined as 17-25 days (Pfizer-BioNTech) and 24-32 days (Moderna) after the first dose. Analyses were stratified by jurisdiction and by demographic characteristics. In the first analysis, among 12,496,258 persons who received the first vaccine dose and for whom sufficient time had elapsed to receive the second dose, 88.0% had completed the series, 8.6% had not received the second dose but remained within the allowable interval (≤42 days since the first dose), and 3.4% had missed the second dose (outside the allowable interval, >42 days since the first dose). The percentage of persons who missed the second dose varied by jurisdiction (range = 0.0%-9.1%) and among demographic groups was highest among non-Hispanic American Indian/Alaska Native (AI/AN) persons (5.1%) and persons aged 16-44 years (4.0%). In the second analysis, among 14,205,768 persons who received a second dose, 95.6% received the dose within the recommended interval, although percentages varied by jurisdiction (range = 79.0%-99.9%). Public health officials should identify and address possible barriers to completing the COVID-19 vaccination series to ensure equitable coverage across communities and maximum health benefits for recipients. Strategies to ensure series completion could include scheduling second-dose appointments at the first-dose administration and sending reminders for second-dose visits. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Vaccination Coverage Among Children in Kindergarten -- United States, 2012-13 School Year.
- Author
-
Seither, Ranee, Shaw, Lauren, Knighton, Cynthia L., Greby, Stacie M., and Stokley, Shannon
- Subjects
- *
VACCINATION of children , *KINDERGARTEN children , *VACCINATION , *MEASLES vaccines , *MUMPS vaccines , *RUBELLA vaccines , *DIPHTHERIA vaccines , *TETANUS vaccines , *HEALTH - Abstract
The article provides data on vaccination coverage among kindergarten children in the U.S. during the 212-2013 school year. According to a report from the Centers for Disease Control and Prevention (CDC), states have school vaccination coverage for measles, mumps and rubella (MMR), diphtheria, tetanus and pertussis (DTaP), and varicella. The report also showed that high and exemption levels remained stable in kindergarten vaccination coverage for the school year.
- Published
- 2013
11. Tobacco Use Screening and Counseling During Physician Office Visits Among Adults -- National Ambulatory Medical Care Survey and National Health Interview Survey, United States, 2005-2009.
- Author
-
Jamal, Ahmed, Dube, Shanta R., Malarcher, Ann M., Shaw, Lauren, and Engstrom, Martha C.
- Subjects
TOBACCO & health ,SMOKING cessation ,HEALTH counseling ,PHYSICIAN services utilization ,MEDICAL screening ,HEALTH surveys - Abstract
The article offers information on the U.S. National Health Interview Survey (NHIS) and National Ambulatory Medical Care Survey (NAMCS) from 2005-2009 concerning tobacco use screening, counseling, and cessation. The data from the surveys was analyzed to determine the percentage of physician office visits made by adults. It shows that tobacco use screening and intervention is a significant component of a strategy to increase cessation.
- Published
- 2012
12. Quitting Smoking Among Adults -- United States, 2001-2010.
- Author
-
Dube, Shanta, Shaw, Lauren, Babb, Stephen, Kaufmann, Rachel, and Malarcher, Ann
- Subjects
- *
SMOKING cessation , *ADULTS , *ANTI-smoking campaigns - Abstract
The article analyzes the report by the National Health Interview Surveys (NHIS) in the U.S. on the effort of adults to quit smoking from 2001 to 2011. It presents the statistical data which shows the number of adults who had stopped smoking, willing to stop smoking and advised by the health professional to quit. It mentions the Million Hearts initiative of the U.S. Department of Health and Human Services which determines the numbers of adults who quit smoking in the U.S.
- Published
- 2011
13. Vital Signs: Current Cigarette Smoking Among Adults Aged ≥ 18 Years -- United States, 2005-2010.
- Author
-
King, Brian, Dube, Shanta, Kaufmann, Rachel, Shaw, Lauren, and Pechacek, Terry
- Subjects
CIGARETTE smokers ,SMOKING ,TOBACCO use ,PUBLIC health - Abstract
Background: Tobacco use remains the leading cause of preventable morbidity and mortality in the United States. Methods: The 2005-2010 National Health Interview Surveys and the 2010 Behavioral Risk Factor Surveillance System survey were used to estimate national and state adult smoking prevalence, respectively. Current cigarette smokers were defined as adults aged ≥18 years who reported having smoked ≥100 cigarettes during their lifetime and who now smoke every day or some days. Results: In 2010, 19.3% of U.S. adults were current cigarette smokers. Higher smoking prevalence was observed in the Midwest (21.8%) and South (21.0%). From 2005 to 2010, the proportion of smokers declined from 20.9% to 19.3% (p<0.05 for trend), representing approximately 3 million fewer smokers in 2010 than would have existed had prevalence not declined since 2005. The proportion of daily smokers who smoked one to nine cigarettes per day (CPD) increased from 16.4% to 21.8% during 2005-2010 (p<0.05 for trend), whereas the proportion who smoked ≥30 CPD decreased from 12.7% to 8.3% (p<0.05 for trend). Conclusions: During 2005-2010, an overall decrease was observed in the prevalence of cigarette smoking among adults; however, the amount and direction of change has not been consistent year-to-year. Implications for Public Health Practice: Enhanced efforts are needed to accelerate the decline in cigarette smoking among adults. Population-based prevention strategies, such as tobacco taxes, media campaigns, and smoke-free policies, in concert with clinical cessation interventions, can help decrease cigarette smoking and reduce the health burden and economic impact of tobacco-related diseases in the United States. [ABSTRACT FROM AUTHOR]
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.